|
MechanismAT1R antagonists |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults
The purpose of this study is to evaluate the Pharmacokinetics, Safety, Tolerability of Nirsevimab in Healthy Chinese Adults.
100 Clinical Results associated with IQVIA RDS (Shanghai) Co. Ltd.
0 Patents (Medical) associated with IQVIA RDS (Shanghai) Co. Ltd.
100 Deals associated with IQVIA RDS (Shanghai) Co. Ltd.
100 Translational Medicine associated with IQVIA RDS (Shanghai) Co. Ltd.